Association between reactogenicity and SARS-CoV-2 antibodies after the second dose of the BNT162b2 COVID-19 vaccine

High vaccine reactogenicities may reflect stronger immune responses, but the epidemiological evidence for coronavirus disease 2019 (COVID-19) vaccines is sparse and inconsistent. We observed that a fever of ≥38℃ after two doses of the BNT162b2 vaccine was associated with higher severe acute respirat...

Descripción completa

Detalles Bibliográficos
Autores principales: Yamamoto, Shohei, Fukunaga, Ami, Tanaka, Akihito, Takeuchi, Junko S., Inoue, Yosuke, Kimura, Moto, Maeda, Kenji, Ueda, Gohzoh, Mizoue, Tetsuya, Ujiie, Mugen, Sugiura, Wataru, Ohmagari, Norio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Ltd. 2022
Materias:
Short Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8841206/
https://www.ncbi.nlm.nih.gov/pubmed/35183384
http://dx.doi.org/10.1016/j.vaccine.2022.02.052
_version_ 1784650786483994624
author Yamamoto, Shohei
Fukunaga, Ami
Tanaka, Akihito
Takeuchi, Junko S.
Inoue, Yosuke
Kimura, Moto
Maeda, Kenji
Ueda, Gohzoh
Mizoue, Tetsuya
Ujiie, Mugen
Sugiura, Wataru
Ohmagari, Norio
author_facet Yamamoto, Shohei
Fukunaga, Ami
Tanaka, Akihito
Takeuchi, Junko S.
Inoue, Yosuke
Kimura, Moto
Maeda, Kenji
Ueda, Gohzoh
Mizoue, Tetsuya
Ujiie, Mugen
Sugiura, Wataru
Ohmagari, Norio
author_sort Yamamoto, Shohei
collection PubMed
description High vaccine reactogenicities may reflect stronger immune responses, but the epidemiological evidence for coronavirus disease 2019 (COVID-19) vaccines is sparse and inconsistent. We observed that a fever of ≥38℃ after two doses of the BNT162b2 vaccine was associated with higher severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike IgG titers.
format Online
Article
Text
id pubmed-8841206
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Elsevier Ltd.
record_format MEDLINE/PubMed
spelling pubmed-88412062022-02-14 Association between reactogenicity and SARS-CoV-2 antibodies after the second dose of the BNT162b2 COVID-19 vaccine Yamamoto, Shohei Fukunaga, Ami Tanaka, Akihito Takeuchi, Junko S. Inoue, Yosuke Kimura, Moto Maeda, Kenji Ueda, Gohzoh Mizoue, Tetsuya Ujiie, Mugen Sugiura, Wataru Ohmagari, Norio Vaccine Short Communication High vaccine reactogenicities may reflect stronger immune responses, but the epidemiological evidence for coronavirus disease 2019 (COVID-19) vaccines is sparse and inconsistent. We observed that a fever of ≥38℃ after two doses of the BNT162b2 vaccine was associated with higher severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike IgG titers. Elsevier Ltd. 2022-03-18 2022-02-14 /pmc/articles/PMC8841206/ /pubmed/35183384 http://dx.doi.org/10.1016/j.vaccine.2022.02.052 Text en © 2022 Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Short Communication
Yamamoto, Shohei
Fukunaga, Ami
Tanaka, Akihito
Takeuchi, Junko S.
Inoue, Yosuke
Kimura, Moto
Maeda, Kenji
Ueda, Gohzoh
Mizoue, Tetsuya
Ujiie, Mugen
Sugiura, Wataru
Ohmagari, Norio
Association between reactogenicity and SARS-CoV-2 antibodies after the second dose of the BNT162b2 COVID-19 vaccine
title Association between reactogenicity and SARS-CoV-2 antibodies after the second dose of the BNT162b2 COVID-19 vaccine
title_full Association between reactogenicity and SARS-CoV-2 antibodies after the second dose of the BNT162b2 COVID-19 vaccine
title_fullStr Association between reactogenicity and SARS-CoV-2 antibodies after the second dose of the BNT162b2 COVID-19 vaccine
title_full_unstemmed Association between reactogenicity and SARS-CoV-2 antibodies after the second dose of the BNT162b2 COVID-19 vaccine
title_short Association between reactogenicity and SARS-CoV-2 antibodies after the second dose of the BNT162b2 COVID-19 vaccine
title_sort association between reactogenicity and sars-cov-2 antibodies after the second dose of the bnt162b2 covid-19 vaccine
topic Short Communication
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8841206/
https://www.ncbi.nlm.nih.gov/pubmed/35183384
http://dx.doi.org/10.1016/j.vaccine.2022.02.052
work_keys_str_mv AT yamamotoshohei associationbetweenreactogenicityandsarscov2antibodiesaftertheseconddoseofthebnt162b2covid19vaccine
AT fukunagaami associationbetweenreactogenicityandsarscov2antibodiesaftertheseconddoseofthebnt162b2covid19vaccine
AT tanakaakihito associationbetweenreactogenicityandsarscov2antibodiesaftertheseconddoseofthebnt162b2covid19vaccine
AT takeuchijunkos associationbetweenreactogenicityandsarscov2antibodiesaftertheseconddoseofthebnt162b2covid19vaccine
AT inoueyosuke associationbetweenreactogenicityandsarscov2antibodiesaftertheseconddoseofthebnt162b2covid19vaccine
AT kimuramoto associationbetweenreactogenicityandsarscov2antibodiesaftertheseconddoseofthebnt162b2covid19vaccine
AT maedakenji associationbetweenreactogenicityandsarscov2antibodiesaftertheseconddoseofthebnt162b2covid19vaccine
AT uedagohzoh associationbetweenreactogenicityandsarscov2antibodiesaftertheseconddoseofthebnt162b2covid19vaccine
AT mizouetetsuya associationbetweenreactogenicityandsarscov2antibodiesaftertheseconddoseofthebnt162b2covid19vaccine
AT ujiiemugen associationbetweenreactogenicityandsarscov2antibodiesaftertheseconddoseofthebnt162b2covid19vaccine
AT sugiurawataru associationbetweenreactogenicityandsarscov2antibodiesaftertheseconddoseofthebnt162b2covid19vaccine
AT ohmagarinorio associationbetweenreactogenicityandsarscov2antibodiesaftertheseconddoseofthebnt162b2covid19vaccine

Ejemplares similares